Tamoxifen
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Tamoxifen: From Breast Cancer to Mammary Paget Disease
One-Sentence Summary
Tamoxifen is a selective estrogen receptor modulator (SERM) originally used to treat estrogen receptor-positive (ER+) breast cancer. The TxGNN model predicts it may also be effective for Mammary Paget Disease, but this is currently supported by only 1 clinical trial (not disease-specific) and 13 publications, most of which are case reports rather than controlled efficacy studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Breast Cancer (ER+) — regulatory indication text unavailable, Data Gap DG001 |
| Predicted New Indication | Mammary Paget Disease |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L3 |
| India Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap DG002, High severity). Based on well-established pharmacological knowledge, Tamoxifen is a Selective Estrogen Receptor Modulator (SERM) that competitively blocks estrogen receptor (ER) signaling in breast tissue. Its efficacy in ER-positive breast cancer has been proven over decades of clinical use, and mechanistically this ER-antagonism may extend to other ER-driven breast pathologies.
Mammary Paget disease frequently coexists with an underlying ER-positive ductal carcinoma in situ (DCIS) or invasive ductal carcinoma beneath the nipple-areola complex. The rationale for using tamoxifen in Paget disease is therefore largely an extension of treating the associated underlying breast malignancy, rather than a distinct mechanism targeting Paget cells themselves.
However, the current evidence pack shows this link is still indirect: the only registered clinical trial (NCT00002920) addresses endometrial monitoring in tamoxifen-treated patients — not efficacy against Paget disease — and the supporting literature consists mainly of individual case reports describing tamoxifen response in hormone receptor-positive Paget lesions. No dedicated randomized controlled trial confirms efficacy specifically for mammary Paget disease.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00002920 | Phase 3 | Completed | 313 | Evaluated medroxyprogesterone vs. observation for preventing endometrial pathology in postmenopausal breast cancer/Paget’s disease patients on tamoxifen — a safety-monitoring trial, not a Paget disease efficacy trial (relevance grade C) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16277886 | 2005 | Cohort | Clin Breast Cancer | Among 2,181 BCT patients, Paget’s disease occurred rarely as a pattern of local recurrence |
| 34463889 | 2022 | Case Report | Investigational New Drugs | HR-positive metastatic extramammary Paget disease successfully treated with tamoxifen |
| 19112575 | 2009 | Case Report | Arch Gynecol Obstet | Rare case of synchronous vulvar and breast Paget’s disease with underlying carcinomas |
| 1648987 | 1991 | Case Report/Review | Br J Surg | Series of 48 women with nipple Paget’s disease; one treated with tamoxifen alone |
| 8955252 | 1996 | Case Report | Am Surg | Male breast Paget’s disease case with review of 32 world-literature cases |
| 25759627 | 2014 | Meta-Analysis | Breast Care (Basel) | Meta-analysis comparing mastectomy vs. BCS+radiotherapy outcomes for breast Paget’s disease |
| 29694313 | 2018 | Case Report | Il Giornale di Chirurgia | Male nipple Paget’s disease case; notes absence of standardized treatment guidelines |
| 12924421 | 2003 | Case Report | Surgery Today | Synchronous bilateral breast cancer with Paget’s disease and invasive ductal carcinoma |
| 14965622 | 2001 | Case Report | Breast (Edinburgh) | Extensive nipple Paget’s disease achieved response with tamoxifen plus radiotherapy |
| 17319355 | 2006 | Case Series | Niger J Clin Pract | Nigerian series: 8/240 breast cancer patients presented with nipple-areola Paget’s disease |
Cytotoxicity
Tamoxifen’s original indication (breast cancer) qualifies it as an antineoplastic agent, but it is a hormonal/targeted agent rather than a conventional cytotoxic chemotherapy drug.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — Hormonal agent (SERM), not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Low — SERMs are not classically myelosuppressive; no drug-specific hematologic toxicity data available in this evidence pack |
| Emetogenicity Classification | Low |
| Monitoring Items | Endometrial monitoring (known class effect — reflected in NCT00002920 above), CBC, liver function, lipid profile, coagulation/thromboembolism risk |
| Handling Protection | Handle per institutional hazardous drug protocols (reproductive toxicant); does not require closed-system cytotoxic infusion handling used for conventional chemotherapy |
Safety Considerations
- Drug Interactions: DDI query completed with 546 total interactions identified. Notable Major-level interactions include: Bupropion, Cimetidine, Cisapride, Dexfenfluramine, Dolasetron, Eliglustat, Fenfluramine, and Lorcaserin. Notable Moderate-level interactions include: Famotidine, Loperamide, Aprepitant, Dexamethasone, Clarithromycin, and Granisetron.
- Key warnings and contraindications are not available in this evidence pack (Data Gap DG001, Blocking severity — TFDA/label data not yet retrieved).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence specific to mammary Paget disease is limited to case reports and mechanistic extrapolation (L3); no dedicated RCT evaluates tamoxifen efficacy for Paget disease itself, and the only registered trial addresses a treatment side effect, not efficacy. Critically, safety labeling data (warnings/contraindications) is a Blocking-severity gap (DG001), preventing progression to a formal safety assessment (S1).
To proceed, the following is needed:
- TFDA-equivalent label data (warnings/contraindications) to resolve Blocking gap DG001
- Confirmed mechanism of action documentation (DG002)
- A dedicated efficacy study (retrospective cohort or prospective trial) in mammary Paget disease specifically
- Note: within this same TxGNN prediction batch, ER-positive breast cancer (rank 9) and breast carcinoma in situ (rank 4) show substantially stronger existing evidence (L1, multiple completed Phase 3 RCTs) and may warrant prioritization over mammary Paget disease for near-term repurposing action
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.